carmustine

Summary

Summary: A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed)

Top Publications

  1. pmc A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma
    Manfred Westphal
    Department of Neurosurgery, University Hospital Eppendorf, Hamburg, Germany
    Neuro Oncol 5:79-88. 2003
  2. pmc Carmustine-induced phosphatidylserine translocation in the erythrocyte membrane
    Kashif Jilani
    Department of Physiology, University of Tuebingen, Gmelinstr 5, Tuebingen D 72076, Germany
    Toxins (Basel) 5:703-16. 2013
  3. ncbi Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: still very long survival but late relapses do occur
    Christian H Geisler
    Rigshospitalet, Copenhagen, Denmark
    Br J Haematol 158:355-62. 2012
  4. ncbi Phase II randomized study of dacarbazine, carmustine, cisplatin and tamoxifen versus dacarbazine alone in advanced melanoma patients
    V Chiarion Sileni
    Department of Medical Oncology, Padova Hospital, Azienda Ospedaliera, Italy
    Melanoma Res 11:189-96. 2001
  5. ncbi Phase III study comparing three cycles of infusional carmustine and cisplatin followed by radiation therapy with radiation therapy and concurrent carmustine in patients with newly diagnosed supratentorial glioblastoma multiforme: Eastern Cooperative Oncol
    Stuart A Grossman
    1650 Orleans St, Room G93, The Sydney Kimmel Cancer Center at Johns Hopkins, Baltimore, MD 21231, USA
    J Clin Oncol 21:1485-91. 2003
  6. ncbi Self-protecting core-shell magnetic nanoparticles for targeted, traceable, long half-life delivery of BCNU to gliomas
    Hung Wei Yang
    Molecular Medicine Research Center, Department of Chemical and Materials Engineering, Chang Gung University, 259 Wen Hwa 1st Road, Kuei Shan, Tao Yuan 33302, Taiwan, ROC
    Biomaterials 32:6523-32. 2011
  7. pmc Efficient and stable MGMT-mediated selection of long-term repopulating stem cells in nonhuman primates
    Brian C Beard
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA
    J Clin Invest 120:2345-54. 2010
  8. ncbi Treatment of single brain metastasis with resection, intracavity carmustine polymer wafers, and radiation therapy is safe and provides excellent local control
    Matthew G Ewend
    University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA
    Clin Cancer Res 13:3637-41. 2007
  9. ncbi Overall survival of newly diagnosed glioblastoma patients receiving carmustine wafers followed by radiation and concurrent temozolomide plus rotational multiagent chemotherapy
    Mary Lou Affronti
    Department of Surgery, Duke University Medical Center, and The Preston Robert Tisch Brain Tumor Center, South Hospital, Durham, North Carolina 27710, USA
    Cancer 115:3501-11. 2009
  10. pmc Effect of protein S-glutathionylation on Ca2+ homeostasis in cultured aortic endothelial cells
    Jeffrey T Lock
    Rammelkamp Center for Education and Research, MetroHealth Medical Center, Department of Physiology and Biophysics, Case Western Reserve University School of Medicine, 2500 MetroHealth Dr, Cleveland, OH 44109, USA
    Am J Physiol Heart Circ Physiol 300:H493-506. 2011

Detail Information

Publications242 found, 100 shown here

  1. pmc A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma
    Manfred Westphal
    Department of Neurosurgery, University Hospital Eppendorf, Hamburg, Germany
    Neuro Oncol 5:79-88. 2003
    ..1% in the BCNU wafer-treated group vs. 1.7% in the placebo group). This study confirms that local chemotherapy with BCNU wafers is well tolerated and offers a survival benefit to patients with newly diagnosed malignant glioma...
  2. pmc Carmustine-induced phosphatidylserine translocation in the erythrocyte membrane
    Kashif Jilani
    Department of Physiology, University of Tuebingen, Gmelinstr 5, Tuebingen D 72076, Germany
    Toxins (Basel) 5:703-16. 2013
    The nitrosourea alkylating agent, carmustine, is used as chemotherapeutic drug in several malignancies. The substance triggers tumor cell apoptosis. Side effects of carmustine include myelotoxicity with anemia...
  3. ncbi Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: still very long survival but late relapses do occur
    Christian H Geisler
    Rigshospitalet, Copenhagen, Denmark
    Br J Haematol 158:355-62. 2012
    ..These results, although highly encouraging regarding the majority of the patients, underline the need of a risk-adapted treatment strategy for MCL. The study was registered at www.isrctn.org as ISRCTN 87866680...
  4. ncbi Phase II randomized study of dacarbazine, carmustine, cisplatin and tamoxifen versus dacarbazine alone in advanced melanoma patients
    V Chiarion Sileni
    Department of Medical Oncology, Padova Hospital, Azienda Ospedaliera, Italy
    Melanoma Res 11:189-96. 2001
    ..phase II trial was performed to define the activity and toxicity of the combination of dacarbazine (DTIC), carmustine (BCNU), cisplatin (DDP) and tamoxifen (DBDT regimen) versus DTIC alone in patients with metastatic melanoma...
  5. ncbi Phase III study comparing three cycles of infusional carmustine and cisplatin followed by radiation therapy with radiation therapy and concurrent carmustine in patients with newly diagnosed supratentorial glioblastoma multiforme: Eastern Cooperative Oncol
    Stuart A Grossman
    1650 Orleans St, Room G93, The Sydney Kimmel Cancer Center at Johns Hopkins, Baltimore, MD 21231, USA
    J Clin Oncol 21:1485-91. 2003
    ..Group-Southwest Oncology Group intergroup study was conducted to determine whether three 72-hour infusions of carmustine (BiCNU) and cisplatin administered monthly before external-beam radiotherapy would improve the survival of ..
  6. ncbi Self-protecting core-shell magnetic nanoparticles for targeted, traceable, long half-life delivery of BCNU to gliomas
    Hung Wei Yang
    Molecular Medicine Research Center, Department of Chemical and Materials Engineering, Chang Gung University, 259 Wen Hwa 1st Road, Kuei Shan, Tao Yuan 33302, Taiwan, ROC
    Biomaterials 32:6523-32. 2011
    ..5 mg BCNU/kg carried by the nanocarrier versus 50 days for those that received 13.5 mg of free-BCNU). This improvement could enhance the potential of magnetic targeting therapy in clinical applications of cancer treatments...
  7. pmc Efficient and stable MGMT-mediated selection of long-term repopulating stem cells in nonhuman primates
    Brian C Beard
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA
    J Clin Invest 120:2345-54. 2010
    ..These nonhuman primate studies closely model a clinical setting and should have broad applications for HSC gene therapy targeting human diseases of malignant, genetic, and infectious nature, including HIV...
  8. ncbi Treatment of single brain metastasis with resection, intracavity carmustine polymer wafers, and radiation therapy is safe and provides excellent local control
    Matthew G Ewend
    University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA
    Clin Cancer Res 13:3637-41. 2007
    To define the safety and efficacy of carmustine polymer wafers when added to a regimen of surgery and external beam radiotherapy for treatment of a single brain metastasis.
  9. ncbi Overall survival of newly diagnosed glioblastoma patients receiving carmustine wafers followed by radiation and concurrent temozolomide plus rotational multiagent chemotherapy
    Mary Lou Affronti
    Department of Surgery, Duke University Medical Center, and The Preston Robert Tisch Brain Tumor Center, South Hospital, Durham, North Carolina 27710, USA
    Cancer 115:3501-11. 2009
    Glioblastoma multiforme (GBM), the most lethal type of brain tumor, has a 1-year median survival. The effect of carmustine wafers on the survival of newly diagnosed GBM patients treated with radiotherapy (RT) and concurrent temozolomide (..
  10. pmc Effect of protein S-glutathionylation on Ca2+ homeostasis in cultured aortic endothelial cells
    Jeffrey T Lock
    Rammelkamp Center for Education and Research, MetroHealth Medical Center, Department of Physiology and Biophysics, Case Western Reserve University School of Medicine, 2500 MetroHealth Dr, Cleveland, OH 44109, USA
    Am J Physiol Heart Circ Physiol 300:H493-506. 2011
    ....
  11. pmc Metallothionein induction reduces caspase-3 activity and TNFalpha levels with preservation of cognitive function and intact hippocampal neurons in carmustine-treated rats
    Gouda K Helal
    Department of Pharmacology, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia
    Oxid Med Cell Longev 2:26-35. 2009
    ..The present study aimed to explore the effect of MT induction on carmustine (BCNU)-induced hippocampal cognitive dysfunction in rats...
  12. ncbi Inhibition of human brain malignant glioblastoma cells using carmustine-loaded catanionic solid lipid nanoparticles with surface anti-epithelial growth factor receptor
    Yung Chih Kuo
    Department of Chemical Engineering, National Chung Cheng University, Chia yi 62102, Taiwan, ROC
    Biomaterials 32:3340-50. 2011
    Innovated catanionic solid lipid nanoparticles (CASLNs) carrying carmustine (BCNU) (BCNU-CASLNs) were grafted with anti-epithelial growth factor receptor (EGFR) (anti-EGFR/BCNU-CASLNs) and applied to inhibiting the propagation of human ..
  13. ncbi Prognostic impact of O6-methylguanine-DNA methyltransferase silencing in patients with recurrent glioblastoma multiforme who undergo surgery and carmustine wafer implantation: a prospective patient cohort
    Philippe Metellus
    Department of Neurosurgery, Timone Hospital, Marseille, France
    Cancer 115:4783-94. 2009
    ..In this study, the authors evaluated the prognostic value of different biomarkers in recurrent GBM and analyzed the changes in MGMT status between primary tumors and recurrent tumors...
  14. ncbi Phase III trial of carmustine and cisplatin compared with carmustine alone and standard radiation therapy or accelerated radiation therapy in patients with glioblastoma multiforme: North Central Cancer Treatment Group 93-72-52 and Southwest Oncology Group
    Jan C Buckner
    Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    J Clin Oncol 24:3871-9. 2006
    In patients with newly diagnosed glioblastoma multiforme, to determine whether cisplatin plus carmustine (BCNU) administered before and concurrently with radiation therapy (RT) improves survival compared with BCNU and RT and whether ..
  15. ncbi Biodegradable carmustine wafers (Gliadel) alone or in combination with chemoradiotherapy: the French experience
    Philippe Menei
    Departement de Neurochirurgie, Inserm U646, CHU d Angers, Angers, France
    Ann Surg Oncol 17:1740-6. 2010
    b>Carmustine-releasing wafers (Gliadel have been available and reimbursed in France since 2005.
  16. pmc Phase I trial of polifeprosan 20 with carmustine implant plus continuous infusion of intravenous O6-benzylguanine in adults with recurrent malignant glioma: new approaches to brain tumor therapy CNS consortium trial
    Jon Weingart
    New Approaches to Brain Tumor Therapy CNS Consortium, Baltimore, MD, USA
    J Clin Oncol 25:399-404. 2007
    ..AGT) levels in brain tumors, (2) evaluate the safety of extending continuous-infusion O6-BG at the optimal dose with intracranially implanted carmustine wafers, and (3) measure the pharmacokinetics of O6-BG and its metabolite.
  17. ncbi Prospective randomized trial of melphalan and prednisone versus vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of primary systemic amyloidosis
    M A Gertz
    Division of Hematology and Internal Medicine, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
    J Clin Oncol 17:262-7. 1999
    ..We investigated whether treatment with multiple alkylating agents improved the response rate or survival time, compared with melphalan and prednisone therapy...
  18. ncbi Phase I trial of high dose paracetamol and carmustine in patients with metastatic melanoma
    Jedd D Wolchok
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Melanoma Res 13:189-96. 2003
    ..We conducted a phase I trial of high dose paracetamol and carmustine (BCNU) in patients with advanced malignant melanoma to determine the optimal biological dose and the maximum ..
  19. ncbi Final analysis of the UKLG LY02 trial comparing 6-8 cycles of CHOP with 3 cycles of CHOP followed by a BEAM autograft in patients <65 years with poor prognosis histologically aggressive NHL
    David C Linch
    NCRI UK Lymphoma Group, CRUK and UCL Cancer Trials Centre UCL, London, UK
    Br J Haematol 149:237-43. 2010
    ..at the time of diagnosis with 223 assigned to continuing CHOP and 234 to 3 cycles of CHOP followed by a BEAM (carmustine, etoposide, cytarabine, melphalan) autograft. Analysis was on an intention to treat basis...
  20. pmc Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034
    Martin J van den Bent
    Neuro Oncology Unit, Daniel den Hoed Cancer Center, PO Box 5201, 3008AE Rotterdam, The Netherlands
    J Clin Oncol 27:1268-74. 2009
    ..In approximately 25% of instances, constitutively activated EGFR mutants are present. These observations make EGFR-inhibiting drugs a logical approach for trials in recurrent GBM...
  21. ncbi Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: report of Radiation Therapy Oncology Group 93-05 protocol
    Luis Souhami
    Department of Oncology, Division of Radiation Oncology, McGill University, Montreal, Quebec, Canada
    Int J Radiat Oncol Biol Phys 60:853-60. 2004
    ..We investigated the effect of stereotactic radiosurgery (SRS) added to conventional external beam radiation therapy (EBRT) with carmustine (BCNU) on the survival of patients with GBM.
  22. ncbi O(6) -methylguanine-DNA methyltransferase (MGMT) promoter methylation and low MGMT-encoded protein expression as prognostic markers in glioblastoma patients treated with biodegradable carmustine wafer implants after initial surgery followed by radiotherap
    Emmanuèle Lechapt-Zalcman
    Department of Pathology, Caen University Hospital, Caen, France
    Cancer 118:4545-54. 2012
    ..However, the prognostic impact of MGMT in patients with newly diagnosed glioblastoma who receive carmustine-releasing wafers (Gliadel) along with temozolomide (TMZ) is still unknown.
  23. ncbi Carmustine wafer implantation when surgical cavity is communicating with cerebral ventricles: technical considerations on a clinical series
    Alessandro Della Puppa
    Department of Neurosurgery, Padua University Hospital, Padova, Italy
    World Neurosurg 76:156-9; discussion 67-8. 2011
    Implantation of carmustine (1,3-bis (2 chloroetyl)-1-nitrosurea [BCNU]) wafers is an approved local treatment after surgical removal of high-grade gliomas. Safety data have been largely reported by phase III studies...
  24. ncbi Carmustine, vincristine, and prednisone in the treatment of canine lymphosarcoma
    Sílvia Regina Ricci Lucas
    Faculdade de Medicina, Veterinária e Zootecnia, Universidade de Sao Paulo, Brazil
    J Am Anim Hosp Assoc 40:292-9. 2004
    A chemotherapeutic protocol using carmustine in combination with vincristine and prednisone was tested in dogs with multicentric malignant lymphosarcoma. Of seven dogs treated, six (85.7%) achieved complete remission...
  25. ncbi Fatal outcome related to carmustine implants in glioblastoma multiforme
    J M Gallego
    Servicio de Neurocirugia, Consorcio Hospital General Universitario de Valencia, Valencia, Spain
    Acta Neurochir (Wien) 149:261-5; discussion 265. 2007
    Following the resection of newly diagnosed or recurrent glioblastomas, local implantation of carmustine-impregnated biodegradable wafers (Gliadel) in the resection cavity constitutes an adjuvant therapy that can improve the possibilities ..
  26. ncbi Quinacrine enhances carmustine therapy of experimental rat glioma
    S Reyes
    Neuroimmunology Unit, , Universidad Nacional Autonoma de Mexico, 14269 Mexico City, Mexico
    Neurosurgery 49:969-73. 2001
    ..We investigated whether quinacrine could improve carmustine therapy in C6 cell cultures and in C6 malignant gliomas implanted subcutaneously into Wistar rats...
  27. ncbi Sensitization of pancreatic tumor xenografts to carmustine and temozolomide by inactivation of their O6-Methylguanine-DNA methyltransferase with O6-benzylguanine or O6-benzyl-2'-deoxyguanosine
    Demetrius M Kokkinakis
    Department of Pathology and the Cancer Institute, The University of Pittsburgh, Pittsburgh, Pennsylvania 15213, USA
    Clin Cancer Res 9:3801-7. 2003
    ..The effect of MGMT inactivation on the resistance of pancreatic tumors to carmustine (BCNU) and to temozolomide (TMZ) was examined in five human pancreatic tumor xenografts in athymic mice...
  28. ncbi Intensive salvage therapy with high-dose chemotherapy for patients with advanced Hodgkin's disease in relapse or failure after initial chemotherapy: results of the Groupe d'Etudes des Lymphomes de l'Adulte H89 Trial
    Christophe Ferme
    Groupe d Etudes des Lymphomes de l Adulte, Hopital Saint Louis, Paris, France
    J Clin Oncol 20:467-75. 2002
    ....
  29. ncbi Protective effect of N-acetylcysteine against carmustine-induced myelotoxicity in rats
    El Sayed M El-Sayed
    Pharmacology and Toxicology Department, Faculty of Pharmacy, Al Azhar University, Cairo, Egypt
    Food Chem Toxicol 48:1576-80. 2010
    b>Carmustine (BCNU) is used to treat a variety of tumors, in particular gliomas. However, the success of such treatment is limited by severe myelosuppression...
  30. ncbi Does high-dose carmustine increase overall survival in supratentorial high-grade malignant glioma? An EBMT retrospective study
    Jacques Olivier Bay
    Unité de transplantation médullaire et département de radiothérapie, Centre Jean Perrin, Clermont Ferrand, France
    Int J Cancer 120:1782-6. 2007
    ..However, prognosis remains poor. High-doses chemotherapy with carmustine is another way to improve response and survival by increasing the dose delivered...
  31. ncbi Initial experience involving treatment and retreatment with carmustine wafers in combination with oral temozolomide: long-term survival in a child with relapsed glioblastoma multiforme
    Javier Márquez-Rivas
    Department of Neurosurgery, Virgen del Rocio University Hospitals, Sevilla, Spain
    J Pediatr Hematol Oncol 32:e202-6. 2010
    ..Glioblastomas occur infrequently in children, and the prognosis is better than for glioblastomas seen in adults. Aggressive treatment is justified in pediatric patients...
  32. ncbi Role of convective flow in carmustine delivery to a brain tumor
    Davis Yohanes Arifin
    Molecular Engineering of Biological and Chemical Systems MEBCS, Singapore MIT Alliance, 4 Engineering Drive 3, Singapore, 117576, Singapore
    Pharm Res 26:2289-302. 2009
    This paper presents a three-dimensional patient-specific simulation of carmustine delivery to brain tumor. The simulation investigates several crucial factors, particularly the role of convective flow, affecting drug delivery efficacy.
  33. ncbi Gliadel therapy given for first resection of malignant glioma: a single centre study of the potential use of Gliadel
    I R Whittle
    Department of Clinical Neurosciences, University of Edinburgh, Western General Hospital, Edinburgh, UK
    Br J Neurosurg 17:352-4. 2003
    ..If the future use of Gliadel is limited to the eligibility criteria used in the phase III trial about 20% (95% confidence intervals 13-34%) of patients with newly diagnosed malignant glioma will receive this therapy...
  34. ncbi Cotreatment with a novel phosphoinositide analogue inhibitor and carmustine enhances chemotherapeutic efficacy by attenuating AKT activity in gliomas
    Timothy E Van Meter
    Department of Neurosurgery, Virginia Commonwealth University, Medical College of Virginia Campus, Richmond, Virginia 23230, USA
    Cancer 107:2446-54. 2006
    ..Selective targeting of AKT, therefore, may increase chemosensitivity. Recently, a novel class of AKT-selective inhibitors has been described, including SH-6, a phosphatidylinositol analogue...
  35. ncbi The sequential use of carmustine wafers (Gliadel®) and post-operative radiotherapy with concomitant temozolomide followed by adjuvant temozolomide: a clinical review
    Sanjay Dixit
    Department of Oncology, Castle Hill Hospital, Hull, UK
    Br J Neurosurg 25:459-69. 2011
    ....
  36. ncbi Buthionine sulfoximine induction of gamma-L-glutamyl-L-cysteine synthetase gene expression, kinetics of glutathione depletion and resynthesis, and modulation of carmustine-induced DNA-DNA cross-linking and cytotoxicity in human glioma cells
    F Ali-Osman
    Department of Experimental Pediatrics, University of Texas M D Anderson Cancer Center, Houston, 77030, USA
    Mol Pharmacol 49:1012-20. 1996
    ..The data also suggest that by preventing GSH resynthesis, a greater level of cytotoxicity is achieved with continuous BSO exposure than with BSO preexposure alone...
  37. ncbi The efficacy of carmustine wafers for older patients with glioblastoma multiforme: prolonging survival
    Kaisorn L Chaichana
    Department of Neurosurgery, The Johns Hopkins Neuro Oncology Surgical Outcomes Research Laboratory, Johns Hopkins University School of Medicine, Baltimore, MD, USA
    Neurol Res 33:759-64. 2011
    Peak incidence of glioblastoma multiforme (GBM) occurs in individuals aged 65 years and older. The goal was to evaluate the efficacy of carmustine wafers in prolonging survival for older GBM patients.
  38. ncbi High-dose carmustine, etoposide, and cisplatin for autologous stem cell transplantation with or without involved-field radiation for relapsed/refractory lymphoma: an effective regimen with low morbidity and mortality
    Punit D Wadhwa
    Department of Medicine, Comprehensive Cancer Center of the University Hospitals of Cleveland Case Western Reserve University, Cleveland, Ohio 44106, USA
    Biol Blood Marrow Transplant 11:13-22. 2005
    ..BEP with or without IFR is a highly effective and well-tolerated regimen in the relapsed/refractory lymphoma setting. It has low morbidity and transplant-related mortality and a low incidence (3%) of posttransplantation malignancy...
  39. ncbi Comparative analysis of temozolomide (TMZ) versus 1,3-bis (2-chloroethyl)-1 nitrosourea (BCNU) in newly diagnosed glioblastoma multiforme (GBM) patients
    Mridula Vinjamuri
    Mary Babb Randolph Cancer Center, West Virginia University, Morgantown, WV 26506, USA
    J Neurooncol 91:221-5. 2009
    ..Although TMZ replaced BCNU as the standard initial chemotherapy in the treatment of GBM, no studies have been reported comparing BCNU with TMZ. We therefore did a retrospective analysis comparing these agents as initial therapy in GBM...
  40. ncbi Carmustine-resistant cancer cells are sensitized to temozolomide as a result of enhanced mismatch repair during the development of carmustine resistance
    Takahiro Yamauchi
    Department of Hematology and Oncology, University of Fukui, 23 Shimoaizuki, Matsuoka, Eiheiji, Fukui 910 1193, Japan
    Mol Pharmacol 74:82-91. 2008
    ..MMR) triggered by O(6)-alkylguanine, whereas MMR protects cells against bifunctional alkylators, including carmustine (BCNU)...
  41. ncbi O6-Benzylguanine potentiates BCNU but not busulfan toxicity in hematopoietic stem cells
    G R Westerhof
    Department of Hematology, Erasmus University, Rotterdam, The Netherlands
    Exp Hematol 29:633-8. 2001
    ..CONCLUSION: These data suggest that BU does not elicit toxicity via alkylation at the O6 position of guanine in DNA in a way that can be influenced by ATase modulation...
  42. ncbi Retrospective comparison of chemoradiotherapy followed by adjuvant chemotherapy, with or without prior gliadel implantation (carmustine) after initial surgery in patients with newly diagnosed high-grade gliomas
    Georges Noel
    Radiation Oncology Department, Centre de Lutte Contre le Cancer Paul Strauss, Strasbourg, France
    Int J Radiat Oncol Biol Phys 82:749-55. 2012
    Retrospective study of patients treated for high-grade glioma, with or without biodegradable carmustine wafers and according to the Stupp protocol.
  43. ncbi Co-delivery of adenovirus and carmustine by anionic liposomes with synergistic anti-tumor effects
    Zhirong Zhong
    Luzhou Medical College, Luzhou, Sichuan, China, 646000
    Pharm Res 29:145-57. 2012
    ..To improve gene transducibility mediated by adenovirus (Ad) in cancer cells and further enhance anti-tumor effects by co-delivery...
  44. ncbi High-dose carmustine, etoposide, and cyclophosphamide followed by allogeneic hematopoietic cell transplantation for non-Hodgkin lymphoma
    Lisa Y Law
    Division of Blood and Marrow Transplantation, Stanford University Medical Center, Stanford, California 94305, USA
    Biol Blood Marrow Transplant 12:703-11. 2006
    ..irradiation and another not based on total body irradiation with preparative therapy using cyclophosphamide, carmustine, and etoposide (CBV) in autologous HCT...
  45. ncbi Dose escalation of carmustine in surgically implanted polymers in patients with recurrent malignant glioma: a New Approaches to Brain Tumor Therapy CNS Consortium trial
    Alessandro Olivi
    The New Approaches to Brain Tumor Therapy CNS Consortium, 1650 Orleans St, Room G93, The Sydney Kimmel Cancer Center at Johns Hopkins, Baltimore, MD 21231, USA
    J Clin Oncol 21:1845-9. 2003
    ..Approaches to Brain Tumor Therapy CNS Consortium study sought to determine the maximum-tolerated dose (MTD) of carmustine (BCNU) that can be implanted in biodegradable polymers following resection of recurrent high-grade gliomas and ..
  46. ncbi Safety and efficacy of permanent iodine-125 seed implants and carmustine wafers in patients with recurrent glioblastoma multiforme
    Borimir J Darakchiev
    Department of Neurosurgery, The Neuroscience Institute, University of Cincinnati Medical Center, Cincinnati, Ohio 45267 0515, USA
    J Neurosurg 108:236-42. 2008
    ..Novel treatment approaches are needed. Localized adjunct treatment with carmustine (BCNU) wafers or permanent, low-activity 125I seed implants has been shown to be effective for GBM...
  47. ncbi Mini-BEAM is effective as a bridge to transplantation in patients with refractory or relapsed Hodgkin lymphoma who have failed to respond to previous lines of salvage chemotherapy but not in patients with salvage-refractory DLBCL
    Sally Moore
    Department of Haematology, University College Hospital, London, UK
    Br J Haematol 157:543-52. 2012
    ..Here we report on 39 such patients who received mini-BEAM (carmustine, etoposide, cytarabine, melphalan) chemotherapy as second or subsequent-line salvage chemotherapy...
  48. ncbi The chemopreventive effect of dimethylthiourea against carmustine-induced myelotoxicity in rats
    El Sayed M El-Sayed
    Pharmacology and Toxicology Department, Faculty of Pharmacy, Al Azhar University, Cairo, Egypt
    Food Chem Toxicol 49:1965-9. 2011
    The possible chemopreventive role of dimethylthiourea (DMTU) against carmustine (1,3-bis(2-chloroethyl)-1-nitrosourea, BCNU)-induced myelotoxicity was assessed through evaluation of apoptosis, lipid peroxidation, glutathione (GSH) content ..
  49. pmc Interstitial docetaxel (taxotere), carmustine and combined interstitial therapy: a novel treatment for experimental malignant glioma
    Prakash Sampath
    Department of Clinical Neurosciences Program in Neurosurgery, Brown Medical School, Rhode Island Hospital, Providence, RI 02903, USA
    J Neurooncol 80:9-17. 2006
    ..Also, we examined the combined local delivery of docetaxel with carmustine (BCNU) against the experimental intracranial glioma...
  50. ncbi Prognostic factors and survival in a prospective cohort of patients with high-grade glioma treated with carmustine wafers or temozolomide on an intention-to-treat basis
    Gregorio Catalán-Uribarrena
    Cruces University Hospital, Baracaldo Vizcaya, Spain
    Acta Neurochir (Wien) 154:211-22; discussion 222. 2012
    Patients with high-grade glioma can be treated with carmustine wafers or following the Stupp protocol. As far as we are aware, no scientific evidence has been published comparing the two treatments...
  51. ncbi Safety and feasibility of the adjunct of local chemotherapy with biodegradable carmustine (BCNU) wafers to the standard multimodal approach to high grade gliomas at first diagnosis
    M Salvati
    Department of Neurosurgery INM Neuromed IRCCS, Pozzilli, Isernia, Italy
    J Neurosurg Sci 55:1-6. 2011
    ....
  52. ncbi Ion dependence of cytotoxicity of carmustine against PC12 cells
    Nina Doroshenko
    Ottawa Health Research Institute, 725 Parkdale Avenue, Ottawa, Ontario, Canada K1Y 4E9
    Eur J Pharmacol 476:185-91. 2003
    Cytotoxicity is a major complication of carmustine (1,3-bis(2-chloroethyl)-1-nitrosourea, BCNU) therapy for treatment of brain tumors and lymphomas...
  53. ncbi In vitro pharmacokinetics and pharmacodynamics of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU)
    Hiroko Ueda-Kawamitsu
    Department of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, 600 South 42nd Street, P O Box 986025, Omaha, NE 68198 6025, USA
    Biochem Pharmacol 63:1209-18. 2002
    ..Because of the disparity between the time-scale of PK and PD, focusing only on the early events may provide limited information about the process of anticancer drug-induced cell death...
  54. ncbi Risk management in the treatment of malignant gliomas with BCNU wafer implants
    A Giese
    Georg August University, Neurosurgery, Goettingen, Germany
    Cent Eur Neurosurg 71:199-206. 2010
    ..The growing body of experience with BCNU wafer implantation may serve as a basis to develop adequate risk management strategies with regard to patient selection, surgical techniques, and follow-up schedules...
  55. ncbi Gliadel (BCNU) wafer plus concomitant temozolomide therapy after primary resection of glioblastoma multiforme
    Matthew J McGirt
    Departments of Neurosurgery, Johns Hopkins School of Medicine, Baltimore, Maryland 21231, USA
    J Neurosurg 110:583-8. 2009
    ..The authors reviewed their initial experience utilizing combined Gliadel, TMZ, and radiation therapy for the treatment of GBM...
  56. ncbi Gliadel wafer in initial surgery for malignant glioma: long-term follow-up of a multicenter controlled trial
    M Westphal
    Department of Neurosurgery, University Hospital Eppendorf, Hamburg, Germany
    Acta Neurochir (Wien) 148:269-75; discussion 275. 2006
    ..The only interstitial chemotherapy treatment approved for malignant glioma is Gliadel wafer containing carmustine (BCNU) placed in the resection cavity at surgery...
  57. ncbi Metallothionein attenuates carmustine-induced oxidative stress and protects against pulmonary fibrosis in rats
    Gouda Kamel Helal
    Department of Pharmacology, College of Pharmacy, King Saud University, P O Box 2457, Riyadh 11451, Saudi Arabia
    Arch Toxicol 83:87-94. 2009
    The present study was carried out to evaluate the effect of exogenously administered metallothionein (MT) against carmustine (BCNU)-induced lung toxicity in rats...
  58. ncbi Temozolomide in combination with BCNU before and after radiotherapy in patients with inoperable newly diagnosed glioblastoma multiforme
    M Barrie
    Unité de Neuro Oncologie, Service de Neurochirurgie, CHU Timone, Assistance Publique Hopitaux de Marseille, Service de Pharmacie, CHU Timone, Cedex France
    Ann Oncol 16:1177-84. 2005
    The aim of this study was to evaluate the efficacy and safety of carmustine (BCNU) in combination with temozolomide as first-line chemotherapy before and after radiotherapy (RT) in patients with inoperable, newly diagnosed glioblastoma ..
  59. ncbi BCNU-loaded PEG-PLLA ultrafine fibers and their in vitro antitumor activity against Glioma C6 cells
    Xiuling Xu
    State Key Laboratory of Polymer Physics and Chemistry, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun 130022, China
    J Control Release 114:307-16. 2006
    ..These results strongly suggest that the BCNU/PEG-PLLA fibers have an effect of controlled release of BCNU and are suitable for postoperative chemotherapy of cancers...
  60. ncbi Combination of intracranial temozolomide with intracranial carmustine improves survival when compared with either treatment alone in a rodent glioma model
    Violette Renard Recinos
    Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    Neurosurgery 66:530-7; discussion 537. 2010
    ..Local delivery of temozolomide (TMZ) through polymers is superior to oral administration in a rodent glioma model...
  61. ncbi Incidence of post transplant myelodysplasia/acute leukemia in non-Hodgkin's lymphoma patients compared with Hodgkin's disease patients undergoing autologous transplantation following cyclophosphamide, carmustine, and etoposide (CBV)
    C Wheeler
    Beth Israel Deaconess Medical Center, Division of Hematology/Oncology, Farber Cancer Institute, MA, USA
    Leuk Lymphoma 40:499-509. 2001
    ..patients with Hodgkin's disease (HD) and non-Hodgkin's lymphoma (NHL) were treated with cyclophosphamide, carmustine and etoposide and autologous stem cell support from 1986 through 1994. Median follow up of survivors is 3...
  62. pmc First-line treatment of malignant glioma with carmustine implants followed by concomitant radiochemotherapy: a multicenter experience
    Hans Christoph Bock
    Department of Neurosurgery, Center of Neurological Medicine, University of Gottingen, Gottingen, Germany
    Neurosurg Rev 33:441-9. 2010
    ..We have compiled the treatment experience of seven neurosurgical centers using implantation of carmustine wafers at primary surgery followed by 6 weeks of radiation therapy (59-60 Gy) and 75 mg/m(2)/day TMZ in patients ..
  63. ncbi Procarbazine, lomustine, and vincristine (PCV) chemotherapy for anaplastic astrocytoma: A retrospective review of radiation therapy oncology group protocols comparing survival with carmustine or PCV adjuvant chemotherapy
    M D Prados
    Department of Neurosurgery, University of California San Francisco, San Francisco, CA 94143 0372, USA
    J Clin Oncol 17:3389-95. 1999
    To determine any differences in outcome for patients with anaplastic astrocytoma (AA) treated with adjuvant carmustine (BCNU) versus procarbazine, lomustine, and vincristine (PCV) chemotherapy.
  64. ncbi The effectiveness of a magnetic nanoparticle-based delivery system for BCNU in the treatment of gliomas
    Mu Yi Hua
    Molecular Medicine Research Center, Department of Chemical and Materials Engineering, Chang Gung University, Tao Yuan, Taiwan, ROC
    Biomaterials 32:516-27. 2011
    ..This drug delivery system promises to provide more effective tumor treatment using lower therapeutic doses and potentially reducing the side effects of chemotherapy...
  65. ncbi Phase I study pilot arms of radiotherapy and carmustine with temozolomide for anaplastic astrocytoma (Radiation Therapy Oncology Group 9813): implications for studies testing initial treatment of brain tumors
    Susan M Chang
    Department of Neurological Surgery, University of California San Francisco, School of Medicine, 400 Parnassus Avenue A808, San Francisco, CA 94143, USA
    Int J Radiat Oncol Biol Phys 59:1122-6. 2004
    To determine the safety and toxicity of carmustine (BCNU) and temozolomide (TMZ) with radiotherapy (RT) in newly diagnosed anaplastic astrocytoma.
  66. ncbi Carmustine wafers: localized delivery of chemotherapeutic agents in CNS malignancies
    Steven H Lin
    Department of Radiation Oncology and Molecular Radiation Sciences, The Johns Hopkins University School of Medicine, 401 North Broadway, Suite 1440, Baltimore, MD 21231, USA
    Expert Rev Anticancer Ther 8:343-59. 2008
    ..To meaningfully increase survival, a trimodality approach of surgery, radiation, and chemotherapy is needed. Carmustine (1,3-bis (2-chloroethyl)-1-nitrosourea) is a nitrosourea alkylating agent that exerts its antitumor effect by ..
  67. ncbi Lack of survival benefit after stereotactic radiosurgery boost for glioblastoma multiforme: randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients
    Dirk Vordermark
    Int J Radiat Oncol Biol Phys 62:296-7; author reply 297. 2005
  68. pmc Methylguanine methyltransferase-mediated in vivo selection and chemoprotection of allogeneic stem cells in a large-animal model
    Tobias Neff
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 1024, USA
    J Clin Invest 112:1581-8. 2003
    ....
  69. ncbi Phase II study of neoadjuvant 1, 3-bis (2-chloroethyl)-1-nitrosourea and temozolomide for newly diagnosed anaplastic glioma: a North American Brain Tumor Consortium Trial
    Susan M Chang
    Department of Neurological Surgery, Neuro Oncology Service, University of California at San Francisco, San Francisco, California 94143, USA
    Cancer 100:1712-6. 2004
    ..The objective of the current study was to determine the efficacy and toxicity profile of a combination of these agents before radiotherapy in newly diagnosed AG...
  70. ncbi O6-benzylguanine-mediated enhancement of chemotherapy
    Henry S Friedman
    Departments of Surgery, Pathology and Medicine, Duke University Medical Center, Room 047, Baker House, Trent Drive, Durham, North Carolina 27710, USA
    Mol Cancer Ther 1:943-8. 2002
    ..These results suggest that a Phase I trial of CPT-11 plus temozolomide plus O6-BG in AGT-positive tumors may be an important intervention to maximize the therapeutic benefits of the combination of CPT-11 and temozolomide...
  71. ncbi Effects on Walker 256 tumour of carmustine associated with a cholesterol-rich microemulsion (LDE)
    Raquel S Teixeira
    Lipid Metabolism Laboratory, the Heart Institute InCor of the Medical School Hospital São Paulo, Brazil
    J Pharm Pharmacol 56:909-14. 2004
    ..LDE can thus serve as a vehicle for drug targeting. It was shown that carmustine side effects are pronouncedly reduced when the drug is associated with LDE in cancer patients...
  72. ncbi In vivo selection and chemoprotection after drug resistance gene therapy in a nonmyeloablative allogeneic transplantation setting in dogs
    Sabine Gerull
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Hum Gene Ther 18:451-6. 2007
    ..Furthermore, the transduced cells conferred chemoprotection and prevented severe neutropenia. Our results suggest that drug resistance gene therapy is feasible and safe in the nonmyeloablative transplantation setting...
  73. ncbi Accumulation of glutathione disulfide mediates NF-kappaB activation during immune stimulation with CpG DNA
    Jeffrey D Kirsch
    Department of Internal Medicine, University of Iowa, Iowa City 52242, USA
    Antisense Nucleic Acid Drug Dev 12:327-40. 2002
    ..These data suggest the existence of a second CpG-induced intracellular signal, independent of GSSG, mediating the activation of innate immunity by bacterial DNA...
  74. ncbi Phase I clinical and pharmacological study of O6-benzylguanine followed by carmustine in patients with advanced cancer
    R L Schilsky
    Department of Medicine, Cancer Research Center and Committee on Clinical Pharmacology, University of Chicago, Illinois 60637, USA
    Clin Cancer Res 6:3025-31. 2000
    ..optimal modulatory dose and associated toxicities of benzylguanine administered alone and in combination with carmustine; to define the maximally tolerated dose and associated toxicities of carmustine administered with benzylguanine ..
  75. ncbi Inhibition of glutathione-related enzymes augments LPS-mediated cytokine biosynthesis: involvement of an IkappaB/NF-kappaB-sensitive pathway in the alveolar epithelium
    John J Haddad
    Department of Anesthesia and Perioperative Care, University of California at San Francisco, School of Medicine, 94143 0542, USA
    Int Immunopharmacol 2:1567-83. 2002
    ....
  76. ncbi Safety profile of carmustine wafers in malignant glioma: a review of controlled trials and a decade of clinical experience
    Michael Sabel
    Department of Neurosurgery, Heinrich Heine University of Dusseldorf, Germany
    Curr Med Res Opin 24:3239-57. 2008
    b>Carmustine (1,3-bis [2-chloroethyl]-1-nitrosourea, or BCNU) wafers are approved for recurrent glioblastoma and newly diagnosed malignant glioma (MG)...
  77. ncbi Chemoimmunohormonal therapy with carmustine, dacarbazine, cisplatin, tamoxifen, and interferon for metastatic melanoma: a prospective phase II study
    Moshe E Stein
    Department of Oncology, Rambam Medical Center, P O B 9602, Haifa 31096, Israel
    Am J Clin Oncol 25:460-3. 2002
    ..Thirty patients entered the study after undergoing a thorough metastatic workup. Treatment protocol included carmustine (BCNU) (150 mg/m(2) IV, day 1) every 6 weeks, dacarbazine (DTIC) (220 mg/m(2) IV, days 1-3), and cisplatin (25 ..
  78. ncbi Phase II trial of carmustine plus O(6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma
    Jennifer A Quinn
    Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
    J Clin Oncol 20:2277-83. 2002
    We conducted a phase II trial of carmustine (BCNU) plus the O(6)-alkylguanine-DNA alkyltransferase inhibitor O(6)-benzylguanine (O(6)-BG) to define the activity and toxicity of this regimen in the treatment of adults with progressive or ..
  79. ncbi A phase III study of radiation therapy plus carmustine with or without recombinant interferon-alpha in the treatment of patients with newly diagnosed high-grade glioma
    J C Buckner
    Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
    Cancer 92:420-33. 2001
    ..study was conducted to determine whether the addition of interferon-alpha (IFN-alpha) to treatment with radiation therapy and carmustine (BCNU) improves time to disease progression or overall survival in patients with high-grade glioma.
  80. ncbi Phase I trial of carmustine plus O6-benzylguanine for patients with recurrent or progressive malignant glioma
    H S Friedman
    Departments of Surgery, Medicine, Pathology, Radiology, and Community and Family Medicine, Duke University Medical Center, Durham, NC 27710, USA
    J Clin Oncol 18:3522-8. 2000
    ..We conducted a phase I trial of carmustine (BCNU) plus O(6)-BG to define the toxicity and maximum-tolerated dose (MTD) of BCNU in conjunction with the ..
  81. pmc A randomized phase III study comparing dacarbazine, BCNU, cisplatin and tamoxifen with dacarbazine and interferon in advanced melanoma
    M R Middleton
    CRC Department of Medical Oncology, Christie Hospital NHS Trust, Manchester, UK
    Br J Cancer 82:1158-62. 2000
    ..75 days/treatment cycle vs 2.29 with dacarbazine and interferon). DBCT combination therapy cannot be recommended as standard treatment for advanced melanoma. Dacarbazine remains the standard chemotherapy for this condition...
  82. ncbi Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first-line temozolomide chemotherapy: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO)
    Alba A Brandes
    Department of Medical Oncology, University Hospital of Padova, Padova, Italy
    J Clin Oncol 22:4779-86. 2004
    ..The aim of the present multicenter phase II trial, therefore, was to ascertain the efficacy of second-line carmustine (BCNU) and irinotecan chemotherapy.
  83. ncbi Association of carmustine with a lipid emulsion: in vitro, in vivo and preliminary studies in cancer patients
    Raul C Maranhão
    The Heart Institute of the Medical School Hospital, University of Sao Paulo, Brazil
    Cancer Chemother Pharmacol 49:487-98. 2002
    ..In this study, the potential of LDE as a carrier for anticancer drugs was investigated...
  84. ncbi A retrospective study of the safety of BCNU wafers with concurrent temozolomide and radiotherapy and adjuvant temozolomide for newly diagnosed glioblastoma patients
    Edward Pan
    Neuro Oncology Division, Moffitt Cancer Center, 12902 Magnolia Drive, MCC NEUROPROG, Tampa, FL 33612 9416, USA
    J Neurooncol 88:353-7. 2008
    ..The efficacy and safety of carmustine (BCNU) wafers followed by radiotherapy have been demonstrated in patients with malignant glioma...
  85. ncbi Pharmacokinetics of the carmustine implant
    Alison B Fleming
    Cornell University, Ithaca, New York, USA
    Clin Pharmacokinet 41:403-19. 2002
    Controlled release delivery of carmustine from biodegradable polymer wafers was approved as an adjunct to surgical resection in the treatment of recurrent glioblastoma multiforme after it was shown in clinical trials to be well tolerated ..
  86. ncbi Semichronic inhibition of glutathione reductase promotes oxidative damage to proteins and induces both transcription and translation of tyrosine hydroxylase in the nigrostriatal system
    Marina Romero-Ramos
    Departamento de Bioquimica, Bromatologia, Toxicologia y Medicina Legal, Facultad de Farmacia, Universidad de Sevilla, C Profesor García GonzAlez s n 41012 Sevilla, Spain
    Free Radic Res 37:1003-12. 2003
    ..All these results support the DA free radical hypothesis and the key role of the striatal glutathione system in protecting the striatal system against oxidative stress...
  87. ncbi Temozolomide and carmustine cause large-scale heterochromatin reorganization in glioma cells
    Roberto Papait
    Dialectica s r l V le Pasteur 10, 20014 Nerviano, Milan, Italy
    Biochem Biophys Res Commun 379:434-9. 2009
    Temozolomide (TMZ) and carmustine (BCNU), cancer-drugs usually used in the treatment of gliomas, are DNA-methylating agents producing O6-methylguanine...
  88. ncbi Synergistic cytotoxicity of the ribonucleotide reductase inhibitor didox (3,4-dihydroxy-benzohydroxamic acid) and the alkylating agent carmustine (BCNU) in 9L rat gliosarcoma cells and DAOY human medulloblastoma cells
    Zsuzsanna Horvath
    General Hospital of Vienna, Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Vienna, 5H Waehringer Guertel 18 20, 1090, Austria
    Cancer Chemother Pharmacol 54:139-45. 2004
    ....
  89. ncbi Pattern of recurrence following local chemotherapy with biodegradable carmustine (BCNU) implants in patients with glioblastoma
    Alf Giese
    Department of Neurosurgery, University Hospital Lubeck, Lubeck, Germany
    J Neurooncol 66:351-60. 2004
    Recently a randomized placebo-controlled phase III trial of biodegradable polymers containing carmustine has demonstrated a significant survival benefit for patients treated with local chemotherapy...
  90. pmc Randomized phase II trial of BCDT [carmustine (BCNU), cisplatin, dacarbazine (DTIC) and tamoxifen] with or without interferon alpha (IFN-alpha) and interleukin (IL-2) in patients with metastatic melanoma
    S R Johnston
    The Melanoma Unit, Royal Marsden NHS Trust, London, UK
    Br J Cancer 77:1280-6. 1998
    ....
  91. pmc Phase I study of Gliadel wafers plus temozolomide in adults with recurrent supratentorial high-grade gliomas
    S Gururangan
    Department of Neurosurgery, Duke University Medical Center, Durham, NC 27710, USA
    Neuro Oncol 3:246-50. 2001
    ..Our study demonstrates that TEMO can be given safely after placement of Gliadel (3.85%) wafers. The recommended dosage for TEMO for a phase II study of this combination is 200 mg/m2 per day for 5 days...
  92. ncbi Synergistic effect of genistein and BCNU on growth inhibition and cytotoxicity of glioblastoma cells
    Sami Khoshyomn
    Department of Surgery, University of Vermont College of Medicine, Burlington 05401, USA
    J Neurooncol 57:193-200. 2002
    ..at a concentration typical of plasma levels following soy diet intake, in combination with 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU, carmustine) exhibited an additive or synergistic inhibitory effect on the growth of glioma cells.
  93. ncbi Acute depletion of reduced glutathione causes extensive carbonylation of rat brain proteins
    Oscar A Bizzozero
    Department of Cell Biology and Physiology, University of New Mexico Health Sciences Center, Albuquerque, New Mexico 87131 5218, USA
    J Neurosci Res 83:656-67. 2006
    ..Our observations may be important in the context of multiple sclerosis where decreased GSH, mitochondrial dysfunction, excessive production of ROS, and increased protein carbonylation have all been reported...
  94. ncbi The glutathione reductase inhibitor carmustine induces an influx of Ca2+ in PC12 cells
    Nina Doroshenko
    Ottawa Health Research Institute, 725 Parkdale Avenue, Ottawa, Ontario K1Y 4E9, Canada
    Eur J Pharmacol 497:17-24. 2004
    We studied the effects of carmustine (1,3-bis(2-chloroethyl)-1-nitrosourea) on the intracellular Ca(2+) concentration ([Ca(2+)](i)) in PC12 cells using fura-2 fluorescence imaging...
  95. ncbi Phase III clinical trial of the combination of cisplatin, dacarbazine, and carmustine with or without tamoxifen in patients with advanced malignant melanoma
    E T Creagan
    Mayo Clinic and Mayo Foundation, Rochester, and Duluth Community Clinical Oncology Program, Duluth, MN 55905, USA
    J Clin Oncol 17:1884-90. 1999
    ..whether the addition of tamoxifen (TAM) to the three-agent regimen of cisplatin (CDDP), dacarbazine (DTIC), and carmustine (BCNU) significantly increased the progression-free survival and overall survival of patients with advanced ..
  96. ncbi Phase II trial of thalidomide and carmustine for patients with recurrent high-grade gliomas
    Howard A Fine
    Neuro Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 10 Center Drive, MSC 1911, Building 10, Room 12S245, Bethesda, MD 20892 1911, USA
    J Clin Oncol 21:2299-304. 2003
    ..synergistic antitumor activity when antiangiogenic agents are combined with cytotoxic agents, we explored the clinical activity of the combination of thalidomide and carmustine (BCNU) in patients with recurrent high-grade gliomas.
  97. ncbi How effective is BCNU in recurrent glioblastoma in the modern era? A phase II trial
    A A Brandes
    Department of Medical Oncology, Azienda Ospedale Universita, Ospedale Busonera, Via Gattamelata 64, 35100 Padova, Italy
    Neurology 63:1281-4. 2004
    ..These drugs remain the standard chemotherapy for glioblastoma. However, because the criteria used to evaluate the activity of nitrosoureas in a neuro-oncologic setting have changed, new data on their activity are needed...
  98. ncbi Phase II trial of carmustine, cisplatin, and oral etoposide chemotherapy before radiotherapy for grade 3 astrocytoma (anaplastic astrocytoma): results of North Central Cancer Treatment Group trial 98-72-51
    Ravi D Rao
    Division of Medical Oncology, Department of Oncology, Mayo Clinic College of Medicine, Rochester, MN 55905 USA
    Int J Radiat Oncol Biol Phys 61:380-6. 2005
    To evaluate the efficacy of preradiotherapy (RT) chemotherapy with carmustine, cisplatin, and oral etoposide combined with RT in the treatment of newly diagnosed anaplastic astrocytoma.
  99. ncbi The Brain Tumor Cooperative Group NIH Trial 87-01: a randomized comparison of surgery, external radiotherapy, and carmustine versus surgery, interstitial radiotherapy boost, external radiation therapy, and carmustine
    Robert G Selker
    Neurosurgery 51:343-55; discussion 355-7. 2002
    ..The objective of the Brain Tumor Cooperative Group NIH Trial 87-01 trial was to investigate the effect of additional implanted radiation therapy in newly diagnosed patients with pathologically confirmed malignant gliomas...
  100. pmc Risk and outcome in metastatic malignant melanoma patients receiving DTIC, cisplatin, BCNU and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha2a
    R Hoffmann
    Department of Hematology and Oncology, Medizinische Hochschule Hannover, Germany
    Br J Cancer 78:1076-80. 1998
    ..Pretreatment risk, as defined by serum lactate dehydrogenase (LDH) and performance status, has a significant impact on treatment outcome and patient survival...
  101. ncbi Association of high-dose cyclophosphamide, cisplatin, and carmustine pharmacokinetics with survival, toxicity, and dosing weight in patients with primary breast cancer
    William P Petros
    Bone Marrow Transplant Program, Duke University Medical Center, Durham, North Carolina 27710, USA
    Clin Cancer Res 8:698-705. 2002
    ..regimen consisting of: cyclophosphamide (1875 mg/m(2) once daily x 3), cisplatin (165 mg/m(2) given over 72 h), carmustine (600 mg/m(2)), and stem cell transplantation...

Research Grants63

  1. Nebraska/Kansas Blood and Marrow Transplant Research Network
    JULIE MARIE VOSE; Fiscal Year: 2013
    ..a phase III randomized clinical trial for patients with relapsed diffuse large B-cell lymphoma using Rituximab/Carmustine, Etoposide, Cytarabine, and Melphalan (R-BEAM) or Bexxar/BEAM + autologous HSCT as the control and R-BEAM or ..
  2. In vivo imaging of encapsulated stem cells in mouse models of tumor resection
    Khalid A Shah; Fiscal Year: 2013
    ..clinical benefit, systemically delivered chemotherapeutic agents or direct injection of viruses and placement of carmustine (BCNU) wafers in tumor resection cavities has provided very limited additional benefit...
  3. Amelioration of Vesicant-Induced Skin Injury by High Dose 25-Hydroxyvitamin D
    Kurt Lu; Fiscal Year: 2013
    ..Direct cutaneous exposure to vesicants such as nitrogen mustard or nitrogen mustard-related nitrosoureas (BCNU (carmustine)) produce dose-dependent symptoms that are varied in onset, severity and duration of wound healing...
  4. Synthesis, Structure and Repair of DNA Interstrand Crosslinks
    ORLANDO D SCHARER; Fiscal Year: 2013
    ..A number of clinically important antitumor agents such as cisplatin, cyclophosphamide (a nitrogen mustard) or carmustine (BCNU, a chloro ethyl nitroso urea) form DNA interstrand crosslinks (ICLs) as key cytotoxic lesions...
  5. Hypoxia-Activated O6-Benzylguanine Prodrugs
    ALAN CLAYTON SARTORELLI; Fiscal Year: 2012
    ..cloretazine), an agent designed and synthesized in our laboratory, currently in late stage clinical trial;carmustine (BCNU) and temozolomide (TMZ), an FDA approved clinically used nitrosourea and methylating agent, respectively, ..
  6. Novel anti-melanoma agents and their mechanism of action
    Harish Joshi; Fiscal Year: 2009
    ..Even combination therapy such as the Dartmouth regimen, which combines dacarbazine with carmustine, cisplatin, and tamoxifen, achieves a response rate of only 40% (Nathan et al., 2000)...
  7. MECHANISMS OF ENHANCEMENT OF MELPHALAN CYTOTOXICITY
    Thomas Guenthner; Fiscal Year: 1993
    ..mustard, LPAM) to human melanoma cells is enhanced by the coadministration of two agents, doxorubicin (DOX) and carmustine (BCNU) ...
  8. SUSTAINED-RELEASE CHEMOTHERAPY FOR OCULAR MALIGNANCY
    HSIAO SU LIU; Fiscal Year: 1980
    ..the effectiveness of nitrosourea compounds, particularly the lipophilic 1, 3-bis(2-chloroethyl)-1-nitrosourea (carmustine, BCNU), against a rabbit model of uveal Greene melanoma...
  9. Prognostic Modeling of High-Risk Primary Breast Cancer
    Yago Nieto; Fiscal Year: 2003
    ..abstract_text> ..
  10. Phase II Study of 44Gy from 131I-81C6 for CNS Tumors
    David Reardon; Fiscal Year: 2004
    ..To further define the toxicity of this approach and Specific Aim 3.To determine the impact of this therapy on quality of life. ..
  11. NABTC Member Intitution Grant (UCSF Project Leader)
    Susan Chang; Fiscal Year: 2008
    ..The overall goal of this program is to more effectively treat patients with primary brain tumors, especially malignant glioma, with the purpose of increasing the duration and quality of survival. ..
  12. Antioxidant Functions of Lipoic Acid
    James May; Fiscal Year: 2004
    ..Despite the widespread use of lipoic acid, these studies are necessary to establish the biological basis and rationale for the clinical use of the agent. ..
  13. Antioxidant vitamins in models of Alzheimer's Disease
    James May; Fiscal Year: 2008
    ..If antioxidant vitamins ameliorate toxicity in cell and animal models of Alzheimer's disease, then oxidant stress is involved in disease progression, and antioxidant vitamin supplements may be beneficial. ..
  14. Therapy of Temodar plus O6-Benzylguanine in Malignant G*
    Jennifer Quinn; Fiscal Year: 2004
    ..abstract_text> ..
  15. AGT DEPLETION FOR THERAPY OF CNS TUMORS
    Jennifer Quinn; Fiscal Year: 2004
    ..abstract_text> ..
  16. Antioxidant Interaction of Selenium and Vitamins C & E
    James May; Fiscal Year: 2008
    ..Using this approach, it will be possible to relate the crucial, mitochondrial functions of selenium and vitamins C and E to the antioxidant defenses of the whole animal. ..
  17. GVHD and Relapse:Ex-Vivo Expanded Allogeneic Therapy
    Sally Arai; Fiscal Year: 2007
    ..unreadable] [unreadable]..
  18. Monoclonal Antibody Therapy for Follicular Lymphoma
    Jonathan Friedberg; Fiscal Year: 2007
    ..abstract_text> ..
  19. CFTR: Probing the Gating Related Movements in the Pore
    Xuehong Liu; Fiscal Year: 2007
    ....
  20. MGMT-Mediated in vivo Selection in a Large Animal Model
    Hans Peter Kiem; Fiscal Year: 2006
    ..These experiments will provide a platform for studies using gene-modified allogeneic stem cells to improve nonmyeloablative transplant strategies. ..
  21. Therapeutic Studies of Primary CNS Malignancies-NABTT
    Gene Barnett; Fiscal Year: 2008
    ..abstract_text> ..
  22. Ap endo as a predictor of response to glioma therapy
    JOHN SILBER; Fiscal Year: 2006
    ..unreadable] [unreadable]..
  23. Ethnic Differences in Survival after Childhood ALL
    Smita Bhatia; Fiscal Year: 2009
    ..abstract_text> ..
  24. INVESTIGATIONS OF MAMMALIAN AMINOPROPYLTRANSFERASES
    ANTHONY PEGG; Fiscal Year: 2009
    ..abstract_text> ..
  25. T Cell Responsiveness and Homeostasis in Anti-Tumor
    Thomas F Gajewski; Fiscal Year: 2010
    ..T cell transduction and tumor transfectants will be examined using factors identified to be useful from the TCR Tg model and mechanisms of improved tumor control will be dissected. ..
  26. Glutaredoxin, Macrophage Death and Atherosclerosis
    RETO H R ASMIS; Fiscal Year: 2010
    ..The proposed studies will test this hypothesis and examine possible molecular mechanisms of Grx-mediated protection of macrophages from mitochondrial dysfunction and cell death. ..
  27. Gene therapy for Fanconi anemia
    Hans Peter Kiem; Fiscal Year: 2009
    ..Our ultimate goal is to improve or cure the hematopoietic symptoms in FA patients by lentivirus-mediated HSC gene transfer, and develop methodologies that would be applicable to other genetic disorders and hematological diseases. ..
  28. Cord Blood Expansion and Transplantation in a Nonhuman Primate Model
    Hans Peter Kiem; Fiscal Year: 2009
    ....
  29. Ape1, oxidative stress and glioma alkylator resistance
    JOHN SILBER; Fiscal Year: 2008
    ..Evidence for a contribution of Ap endo to resistance would identify a new target for anti-resistance strategies directed against Ape1/Ref-1 (the major human Ap endo), either alone or together with MGMT. ..
  30. UROLITHIASIS AND PEROXIDATIVE INJURY
    Sivagnanam Thamilselvan; Fiscal Year: 2008
    ..These studies will provide valuable information on the importance of antioxidants and, whether antioxidants offer promise as a therapeutic agent for recurrent stone formers. ..
  31. Temodar Resistance in CNS Tumors
    Henry Friedman; Fiscal Year: 2008
    ..abstract_text> ..
  32. NABTC CENTRAL OPERATION GRANT (UCSF PROJECT LEADER)
    Michael Prados; Fiscal Year: 2008
    ..The NABTC will treat patients using novel therapeutic agents with the ultimate goal to increase quality, and hopefully, overall survival in this patient population. ..
  33. OXIDATIVE EVENTS IN CANCER THERAPY
    Larry Oberley; Fiscal Year: 2005
    ....
  34. Molecular Dissection of T Cell Anergy
    Thomas Gajewski; Fiscal Year: 2005
    ..Ultimately, a complete understanding of the anergic state on the molecular level should guide the development of novel pharmacologic therapies to promote or reverse peripheral tolerance in vivo. ..
  35. LONG-TERM OUTCOME OF BLOOD AND MARROW TRANSPLANTATION
    J Rizzo; Fiscal Year: 2003
    ..abstract_text> ..
  36. PEDIATRIC BRAIN TUMOR CLINICAL TRIALS CONSORTIUM
    Henry Friedman; Fiscal Year: 2003
    ..abstract_text> ..
  37. BONE MARROW TRANSPLANT (BMT) SURVIVORS STUDY
    Smita Bhatia; Fiscal Year: 2003
    ..g., second cancers, births, cardiac complications, etc.) that may have occurred since the completion of the initial questionnaire. ..
  38. ZD1839 Therapy of Glioblastoma Multiforme
    Henry Friedman; Fiscal Year: 2002
    ....
  39. COMBATING ALKYLATING AGENT RESISTANCE IN HUMAN GLIOMAS
    JOHN SILBER; Fiscal Year: 2002
    ..In an effort to define the role of 3-MAG in clinical drug resistance, enzyme levels will be correlated with response to alkylator adjuvant therapy and clinical course. ..
  40. NITRIC OXIDE, PLP ACYLATION & THE PATHOPHYSIOLOGY OF MS
    OSCAR BIZZOZERO; Fiscal Year: 2003
    ..abstract_text> ..
  41. GI BARRIER HEAT INJURY--SYSTEMIC & MOLECULAR MECHANISMS
    Larry Oberley; Fiscal Year: 2002
    ..2. HSP protection. Cells expressing elevated HSP will also be tested in the above properties as well as the barrier function of acclimated rats. ..
  42. Keystone Symposium on Stroke, March 9-14, 2002
    Chung Hsu; Fiscal Year: 2002
    ..This conference, focusing on fundamental basic science on stroke, will be a much needed vehicle to advance stroke research. ..
  43. INFLAMMATORY APOPTOSIS AFTER SPINAL CORD INJURY
    Chung Hsu; Fiscal Year: 2001
    ..The ultimate goal of this project is to enhance functional recovery after SCI through a reduction in ODC death. ..
  44. INTEGRIN SIGNALING IN ACUTE LYMPHOBLASTIC LEUKEMIA
    Arnold Freedman; Fiscal Year: 2001
    ..Understanding the cell-cell interaction between BM stromal cells and pre-B ALL cells may provide future therapeutic strategies with which to modulate the growth of these leukemias. ..
  45. PEDIATRIC BRAIN TUMOR CLINICAL TRIAL CONSORTIUM
    Michael Prados; Fiscal Year: 2003
    ..The aim of these treatment approaches is to increase disease-free and overall survival in children with brain tumors. ..
  46. INVESTIGATING THE MECHANISMS OF PRB TUMOR SUPPRESSION
    Arnab Chakravarti; Fiscal Year: 2003
    ..Specific Aim number 3: To determine whether the deregulation of E2F dependent transcription is correlated with the tumorigenic potential of RB -/- cells in-vivo. ..
  47. Etanercept Therapy in Follicular Lymphoma
    Arnold Freedman; Fiscal Year: 2003
    ..This study is a novel approach to treating FL, where targeting the microenvironment of the tumor may inhibit the growth and survival of the neoplastic cells. ..
  48. CpG Plus Rituximab Therapy in Follicular Lymphoma
    Arnold Freedman; Fiscal Year: 2005
    ..This study is a novel approach to treating FL, where augmenting antigen presentation and effector cells may lead to enhanced cytotoxic effects of rituximab and induce anti-tumor immunity. ..
  49. Biochemical/Molecular Changes Upon Naive T Cell Priming
    Thomas Gajewski; Fiscal Year: 2005
    ....
  50. Regional AGT Depeltion of CNS and Leptomeningeal Tumors
    Henry Friedman; Fiscal Year: 2005
    ..To define the role of intrathecal AGT inhibitors in enhancing system or intrathecal temozolomide therapy of neoplastic meningitis. ..
  51. CALGB STUDIES OF BREAST CANCER IN THE ELDERLY
    Richard Schilsky; Fiscal Year: 2004
    ..This well integrated project provides a multidisciplinary approach that will address many issues relevant to the treatment of elderly women with breast cancer. ..
  52. Hematopoietic Potential of Muscle-Derived Cells
    Hans Peter Kiem; Fiscal Year: 2004
    ..abstract_text> ..
  53. DNA ADDUCTS FORMED DURING BRAIN TUMOR THERAPY
    William Bodell; Fiscal Year: 2001
    ..Number of treatment. These studies will be the first to investigate the formation of BCNU derived DNA abducts in a ic. Brain tumor model. ..
  54. NABTT-Consortium Therapeutic Studies of CNS Malignancies
    Stuart Grossman; Fiscal Year: 2008
    ..abstract_text> ..
  55. Genomics Screening for Antiangiogenesis Drugs
    John Fruehauf; Fiscal Year: 2002
    ..The total global market size for anti-angiogenesis drugs in cancer could reach $ 3 billion by 2005...
  56. NITROXIDERGIC CEREBROVASCULAR TONE DURING ANESTHESIA
    Shailendra Joshi; Fiscal Year: 2005
    ..abstract_text> ..
  57. GLIOMA HETEROGENEITY AND CHEMOSENSITIVITY
    Adrienne Scheck; Fiscal Year: 2002
    ..The clinical significance of these findings will be validated in fresh frozen and paraffin embedded samples by analyzing tissue from their extensive tumor bank (Specific Aim 4). ..
  58. Probing the pore of CFTR using chemical modification
    Xuehong Liu; Fiscal Year: 2003
    ..mechanism to explain how HFS type diets cause insulin resistance. and hypertension, and how a LFCC diet, antioxidant therapy or exercise training aid in the control of insulin resistance and hypertension. ..
  59. DNA Adducts Formed by Dopamine
    William Bodell; Fiscal Year: 2004
    ..In addition, the results of these studies will provide unique molecular markers that will be used in future studies to evaluate whether this process is occurring in the substantia nigra of human brain. ..
  60. Technologies To Block Gene Expression in Normal T Cells
    Thomas Gajewski; Fiscal Year: 2003
    ..abstract_text> ..
  61. Multi-Peptide/IL 12 Melanoma Vaccine
    Thomas Gajewski; Fiscal Year: 2006
    ..Understanding these mechanisms will illuminate the next level of intervention to develop to increase the clinical response to the immunotherapy of melanoma. [unreadable] [unreadable]..
  62. MECHANISMS OF NO-MEDIATED PROTEIN S-NITROSYLATION IN EAE
    OSCAR BIZZOZERO; Fiscal Year: 2007
    ..abstract_text> ..